Novartis' Afinitor Goes To Panel Review With Trouble Areas For FDA

The Oncology Drugs Advisory Committee will review everolimus for certain advanced neuroendocrine tumors on April 12; the pivotal trial used progression-free survival and a crossover design, both areas that FDA has critiqued.